Coactivation of KRAS and MYC enhances the secretion of tumor-derived CCL9 and IL-23, driving stromal reprogramming, promoting angiogenesis, and excluding tumor-infiltrating T, B, and NK cells [67]. The gene discussed is KRAS; the disease is neoplasm.